In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 3, 2003, Pages 1251-1262

  Egnell, Ann Charlotte ^a,b   Houston, Brian ^b   Boyer, Scott ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450 3A; DRUG METABOLITE; FELBAMATE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL; STEADY STATE;

CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; META-ANALYSIS; MICROSOMES, LIVER; PROPYLENE GLYCOLS;

EID: 0037799740     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047530     Document Type: Article

References (56)

1. Albani F, Theodore WH, Washington P, Devinsky O, Bromfield E, Porter RJ, and Nice FJ (1991) Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 32:130-132.
2. Benet LZ, Kroetz DL, and Sheiner LB (1996a) Pharmacokinetics: The dynamics of drug absorption, distribution and elimination, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Goodman Gilman A, and Limbird LE eds) pp 3-27, McGraw-Hill, New York.
3. Benet LZ, Oie S, and Schwartz JB (1996b) Design and optimization of dosage regimens: Pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Goodman Gilman A, and Limbird LE eds) pp 1707-1792, McGraw-Hill, New York.
4. Bertilsson L, Tomson T, and Tybring G (1986) Pharmacokinetics: time-dependent changes-autoinduction of carbamazepine epoxidation. J Clin Pharmacol 26:459-462.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, and Tyrer JH (1977) The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol 12:451-456.
7. Domanski TL, He YA, Harlow GR, and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585-591.
8. Eichelbaum M, Tomson T, Tybring G, and Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10:80-90.
9. Engman HA, Lennernas H, Taipalensuu J, Otter C, Leidvik B, and Artursson P (2001) CYP3A4, CYP3A5 and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci 90:1736-1751.
10. Faigle JW and Feldmann KF (1989) Carbamazepine biotransformation, in Antiepileptic Drugs (Levy R, Mattson R, Meldrum B, Penry JK, and Dreifuss FE eds) pp 491-504, Raven Press, Ltd., New York.
11. Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, and Remmel RP (1988) Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 29:488-491.
12. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30: 1512-1522.
13. Graves NM, Holmes GB, Fuerst RH, and Leppik IE (1989) Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 30:225-229.
14. Heid CA, Stevens J, Livak KJ, and Williams PM (1996) Real time quantitative PCR. Genome Res 6:986-994.
15. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
16. Houston JB (1986) Drug metabolite kinetics, in Pharmacokinetics: Theory and Methodology (Rowland M and Tucker G eds) pp 131-162, Pergamon Press, Oxford.
17. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
18. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
19. Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, and Tracy TS (2001) Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci 14:47-52.
20. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
21. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
22. Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644-1651.
23. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, and Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
24. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
25. Lasker JM, Huang MT, and Conney AH (1982) In vivo activation of zoxazolamine metabolism by flavone. Science (Wash DC) 216:1419-1421.
26. Lasker JM, Huang MT, and Conney AH (1984) In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J Pharmacol Exp Ther 229:162-170.
27. Lee CA, Lillibridge JH, Nelson SD, and Slattery JT (1996) Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. J Pharmacol Exp Ther 277:287-291.
28. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al. (1991) Felbamate for partial seizures: results of a controlled clinical trial. Neurology 41:1785-1789.
29. Maenpaa J, Hall SD, Ring BJ, Strom SC, and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
30. Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, and Andersson TB (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 27:1117-1122.
31. Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie TA, and Tang W (2001) In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos 29:877-886.
32. Ngui JS, Tang W, Stearns RA, Shou M, Miller RR, Zhang Y, Lin JH, and Baillie TA (2000) Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043-1050.
33. Ogiso T, Ito Y, Iwaki M, and Horibe Y (1990) Inhibitory effect of valproic acid on metabolic clearance of carbamazepine epoxide. J Pharmacobiodyn 13:238-245.
34. Pisani F, Fazio A, Oteri G, Spina E, Perucca E, and Bertilsson L (1988) Effect of valpromide on the pharmacokinetics of carbamazepine-10,11-epoxide. Br J Clin Pharmacol 25:611-613.
35. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:577-587.
36. Remmel RP, Sinz MW, and Cloyd JC (1990) Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. Pharm Res (NY) 7:513-517.
37. Robbins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, and Chang SL (1990) Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 29:759-762.
38. Sachdeo R, Narang-Sachdeo SK, Shumaker RC, Perhach JL, Lyness WH, and Rosenberg A (1997) Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. Epilepsia 38:887-892.
39. Segel IH (1975) Enzyme Kinetics, Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc., New York.
40. Segelman FH, Kelton E, Terzi RM, Kucharczyk N, and Sofia RD (1985) The comparative potency of phenobarbital and five 1,3-propanediol dicarbamates for hepatic cytochrome P450 induction in rats. Res Commun Chem Pathol Pharmacol 48:467-470.
41. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
42. Sumi M, Watari N, Umezawa O, and Kaneniwa N (1987) Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. J Pharmacobiodyn 10:652-661.
43. Swinyard EA, Woodhead JH, Franklin MR, Sofia RD, and Kupferberg HJ (1987) The effect of chronic felbamate administration on anticonvulsant activity and hepatic drug-metabolizing enzymes in mice and rats. Epilepsia 28:295-300.
44. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
45. Theodore WH, Raubertas RF, Porter RJ, Nice F, Devinsky O, Reeves P, Bromfield E, Ito B, and Balish M (1989) Felbamate: a double-blind placebo controlled three-period cross-over trial (Abstract). Epilepsia 30:661.
46. Theodore WH, Raubertas RF, Porter RJ, Nice F, Devinsky O, Reeves P, Bromfield E, Ito B, and Balish M (1991) Felbamate: a clinical trial for complex partial seizures. Epilepsia 32:392-397.
47. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving CYP3A4. Annu Rev Pharmacol Toxicol 38:389-430.
48. Tomson T, Tybring G, and Bertilsson L (1983) Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther 33:58-65.
49. Tybring G, von Bahr C, Bertilsson L, Collste H, Glaumann H, and Solbrand M (1981) Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab Dispos 9:561-564.
50. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
51. Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, and Leppik IE (1991) Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 32:398-406.
52. Wagner ML, Remmel RP, Graves NM, and Leppik IE (1993) Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 53:536-543.
53. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
54. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, and Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355.
55. Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, and Levy RH (1985) Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 26:602-606.
56. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.